ID   HCC1806rGEM20
AC   CVCL_D6VH
SY   HCC1806 rGemcitabine20
RX   DOI=10.1101/2024.01.20.576412;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Part of: Resistant Cancer Cell Line (RCCL) collection.
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr256Lysfs*90 (c.766_767insAA); Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
DI   NCIt; C40359; Breast squamous cell carcinoma, acantholytic variant
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1258 ! HCC1806
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 10-09-24; Last updated: 10-09-24; Version: 1
//
RX   DOI=10.1101/2024.01.20.576412;
RA   Grimsley H.E., Antczak M., McLaughlin K.-M., Nist A., Mernberger M.,
RA   Stiewe T., Speidel D., Cox K., Cinatl J. Jr., Wass M.N., Garrett M.D.,
RA   Michaelis M.;
RT   "Resistance patterns in drug-adapted cancer cell lines reflect complex
RT   evolution in clinical tumors.";
RL   bioRxiv 2024:01.20.576412-01.20.576412(2024).
//